Prophylactic mezlocillin-netilmicin combination in permanent transvenous cardiac pacemaker implantation: a single-center, prospective, randomized study.
A prospective, randomized study was carried out in order to assess the efficacy and safety of the mezlocillin-netilmicin combination in the prophylaxis of first permanent transvenous cardiac pacemaker implantation. Five hundred and fifty-two consecutive patients were randomly administered either 2 g mezlocillin and 200 mg netilmicin both as an i.v. bolus before implantation or 2g mezlocillin before and then 6 and 12 hours after surgery and 200 mg netilmicin before and then 12 hours after implantation. No adverse events were seen. Neither pocket nor electrode infections were observed in the 457 subjects still alive (mean follow-up: 29.2 months) or in patients who died after 1 year of follow-up (mean follow-up: 20.1 months) or before this time (mean follow-up: 4.7 months). The serum and pocket concentrations of mezlocillin and netilmicin at the end of surgery were found to be adequate to cover microorganisms that most often cause infections, including methicillin-resistant staphylococci.
De Lalla
F
F
Division of Infectious Disease, S. Anna Hospital, Como, Italy.
Bonini
W
W
Broffoni
T
T
Ferrari
G
G
Alegente
G
G
D001424:Bacterial Infections / Q000517:prevention & control* / Q000628:therapy; D004359:Drug Therapy, Combination / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007275:Injections, Intravenous; D008802:Mezlocillin / Q000008:administration & dosage / Q000627:therapeutic use*; D009428:Netilmicin / Q000008:administration & dosage / Q000627:therapeutic use*; D010138:Pacemaker, Artificial; D011183:Postoperative Complications / Q000517:prevention & control*; D011292:Premedication; D011446:Prospective Studies; D012307:Risk Factors
D009428:Netilmicin; D008802:Mezlocillin